Caroline Robert.

All other efficacy analyses were based on data from all 135 patients. By September 6 Patients were contained in the analysis if indeed they received a first dose of study medication, 2012. Efficacy and basic safety data that were available as of February 1, 2013, were included in all the analyses. The efficacy analysis included two end factors: overall responses produced from investigator-reported data, with assessment according to immune-related response criteria 11; and general responses derived from independent, central, blinded radiologic review, with assessment according to the Response Evaluation Requirements in Solid Tumors , version 1.1 .12 The entire response rate was defined as the number of sufferers with a complete or partial response divided by the full total number of individuals who acquired measurable disease at baseline and received at least one treatment dose.Outcomes The primary trial outcomes are summarized in Table 3Table 3Clinical Outcomes at thirty days., in addition to in Fig. S2, S3, and S4 in the Supplementary Appendix. The principal outcome occurred in 5.1 percent of the individuals in the bivalirudin group and 8.5 percent in the control group with optional usage of glycoprotein IIb/IIIa inhibitors . The price of occurrence of the main secondary outcome was 6.6 percent in the bivalirudin group and 9.2 percent in the control group .